Cargando…

Conservative Iron Chelation for Neuroferritinopathy

BACKGROUND: Neuroferritinopathy is a rare inherited neurodegenerative disease with brain iron accumulation characterized by brain iron overload resulting in progressive movement disorders. No treatment is currently available. OBJECTIVE: We assessed conservative iron chelation with deferiprone at 30 ...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchand, Felix, Moreau, Caroline, Kuchcinski, Gregory, Huin, Vincent, Defebvre, Luc, Devos, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360136/
https://www.ncbi.nlm.nih.gov/pubmed/35996824
http://dx.doi.org/10.1002/mds.29145
_version_ 1785076036234379264
author Marchand, Felix
Moreau, Caroline
Kuchcinski, Gregory
Huin, Vincent
Defebvre, Luc
Devos, David
author_facet Marchand, Felix
Moreau, Caroline
Kuchcinski, Gregory
Huin, Vincent
Defebvre, Luc
Devos, David
author_sort Marchand, Felix
collection PubMed
description BACKGROUND: Neuroferritinopathy is a rare inherited neurodegenerative disease with brain iron accumulation characterized by brain iron overload resulting in progressive movement disorders. No treatment is currently available. OBJECTIVE: We assessed conservative iron chelation with deferiprone at 30 mg/kg/day on the disease progression with controlled periods of discontinuation. METHODS: Four patients with confirmed molecular diagnosis of neuroferritinopathy were given deferiprone at different stages of disease progression and with clinical and biological monitoring to control benefit and risk. RESULTS: The four patients showed slight to high improvement. In one case, we managed to stabilize disease progression for more than 11 years. In another case, we were able to reverse symptoms after a few months of treatment. The earliest the treatment was started, the most efficient it was on disease progression. CONCLUSIONS: Conservative iron chelation should be further assessed in neuroferritinopathy. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
format Online
Article
Text
id pubmed-10360136
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-103601362023-07-22 Conservative Iron Chelation for Neuroferritinopathy Marchand, Felix Moreau, Caroline Kuchcinski, Gregory Huin, Vincent Defebvre, Luc Devos, David Mov Disord Regular Issue Articles BACKGROUND: Neuroferritinopathy is a rare inherited neurodegenerative disease with brain iron accumulation characterized by brain iron overload resulting in progressive movement disorders. No treatment is currently available. OBJECTIVE: We assessed conservative iron chelation with deferiprone at 30 mg/kg/day on the disease progression with controlled periods of discontinuation. METHODS: Four patients with confirmed molecular diagnosis of neuroferritinopathy were given deferiprone at different stages of disease progression and with clinical and biological monitoring to control benefit and risk. RESULTS: The four patients showed slight to high improvement. In one case, we managed to stabilize disease progression for more than 11 years. In another case, we were able to reverse symptoms after a few months of treatment. The earliest the treatment was started, the most efficient it was on disease progression. CONCLUSIONS: Conservative iron chelation should be further assessed in neuroferritinopathy. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. John Wiley & Sons, Inc. 2022-08-22 2022-09 /pmc/articles/PMC10360136/ /pubmed/35996824 http://dx.doi.org/10.1002/mds.29145 Text en © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Regular Issue Articles
Marchand, Felix
Moreau, Caroline
Kuchcinski, Gregory
Huin, Vincent
Defebvre, Luc
Devos, David
Conservative Iron Chelation for Neuroferritinopathy
title Conservative Iron Chelation for Neuroferritinopathy
title_full Conservative Iron Chelation for Neuroferritinopathy
title_fullStr Conservative Iron Chelation for Neuroferritinopathy
title_full_unstemmed Conservative Iron Chelation for Neuroferritinopathy
title_short Conservative Iron Chelation for Neuroferritinopathy
title_sort conservative iron chelation for neuroferritinopathy
topic Regular Issue Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360136/
https://www.ncbi.nlm.nih.gov/pubmed/35996824
http://dx.doi.org/10.1002/mds.29145
work_keys_str_mv AT marchandfelix conservativeironchelationforneuroferritinopathy
AT moreaucaroline conservativeironchelationforneuroferritinopathy
AT kuchcinskigregory conservativeironchelationforneuroferritinopathy
AT huinvincent conservativeironchelationforneuroferritinopathy
AT defebvreluc conservativeironchelationforneuroferritinopathy
AT devosdavid conservativeironchelationforneuroferritinopathy